VCMCVC Market Cap
Menu

Tubulis valuation, funding and investors

tubulis.com ↗LinkedIn ↗

Tubulis works in antibody-drug conjugate development, based in Planegg, Germany. Founded in 2016, it has about 77 employees.

Pharmaceutical Products Planegg Series C
VALUATION · TODAY
$2.72B +0% after Series C
Range $1.82B – $3.13B · Grade A
TODAY
+12 MO
$1.00B
$2.00B
$3.00B
$4.00B
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series B $139M
Series C $358M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY77 employees
−1%6m growth
+12%1y growth
+64%2y growth
50
100
150
Data from Jan 2021
TODAY
Predicted in 1 yr $2.72B +0% vs today
Predicted next raise $326M if a round comes
Winding-down probability 0%
Last round
Series C · $358M · Oct 2025
Valuation at last round
$2.10B
Headcount
77 · up
Grade
A
Founded
2016
How VCMC values companies →

Tubulis valuation today

VCMC values Tubulis at $2.7B today, with a range of $1.8B to $3.1B and a grade of A. The valuation starts from its last funding round, a Series C round in Oct 2025.

Valuation by date (133 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Tubulis: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 2016$3.45M$1.25M – $9.47M$4.13M (+20%)before first round–unknownD0%
1 Feb 2016$3.46M$1.26M – $9.50M$4.24M (+23%)before first round–unknownD0%
1 Mar 2016$3.47M$1.26M – $9.54M$4.35M (+25%)before first round–unknownD0%
1 Apr 2016$3.49M$1.27M – $9.58M$4.47M (+28%)before first round–unknownD0%
1 May 2016$3.50M$1.27M – $9.61M$4.59M (+31%)before first round–unknownD0%
1 Jun 2016$3.51M$1.28M – $9.65M$4.71M (+34%)before first round–unknownD0%
1 Jul 2016$3.53M$1.28M – $9.69M$4.83M (+37%)before first round–unknownD0%
1 Aug 2016$3.62M$1.32M – $9.95M$4.96M (+37%)before first round–unknownD0%
1 Sep 2016$3.72M$1.35M – $10.2M$5.10M (+37%)before first round–unknownD0%
1 Oct 2016$3.82M$1.39M – $10.5M$5.23M (+37%)before first round–unknownD0%
1 Nov 2016$3.92M$1.43M – $10.8M$5.38M (+37%)before first round–unknownD0%
1 Dec 2016$4.02M$1.46M – $11.1M$5.52M (+37%)before first round–unknownD0%
1 Jan 2017$4.13M$1.50M – $11.3M$5.66M (+37%)before first round–unknownD0%
1 Feb 2017$4.24M$1.54M – $11.7M$5.82M (+37%)before first round–unknownD0%
1 Mar 2017$4.35M$1.58M – $11.9M$5.96M (+37%)before first round–unknownD0%
1 Apr 2017$4.46M$1.63M – $12.3M$6.12M (+37%)before first round–unknownD0%
1 May 2017$4.58M$1.67M – $12.6M$6.28M (+37%)before first round–unknownD0%
1 Jun 2017$4.71M$1.71M – $12.9M$6.45M (+37%)before first round–unknownD0%
1 Jul 2017$4.83M$1.76M – $13.3M$6.62M (+37%)before first round–unknownD0%
1 Aug 2017$4.96M$1.81M – $13.6M$6.80M (+37%)before first round–unknownD0%
1 Sep 2017$5.10M$1.85M – $14.0M$6.99M (+37%)before first round–unknownD0%
1 Oct 2017$5.23M$1.90M – $14.4M$7.17M (+37%)before first round–unknownD0%
1 Nov 2017$5.37M$1.96M – $14.8M$7.36M (+37%)before first round–unknownD0%
1 Dec 2017$5.51M$2.01M – $15.1M$7.56M (+37%)before first round–unknownD0%
1 Jan 2018$5.66M$2.06M – $15.6M$7.76M (+37%)before first round–unknownD0%
1 Feb 2018$5.82M$2.12M – $16.0M$7.97M (+37%)before first round–unknownD0%
1 Mar 2018$5.96M$2.17M – $16.4M$8.17M (+37%)before first round–unknownD0%
1 Apr 2018$6.12M$2.23M – $16.8M$8.39M (+37%)before first round–unknownD0%
1 May 2018$6.28M$2.29M – $17.3M$8.61M (+37%)before first round–unknownD0%
1 Jun 2018$6.45M$2.35M – $17.7M$8.85M (+37%)before first round–unknownD0%
1 Jul 2018$6.62M$2.41M – $18.2M$9.08M (+37%)before first round–unknownD0%
1 Aug 2018$6.80M$2.48M – $18.7M$9.17M (+35%)before first round–unknownD0%
1 Sep 2018$6.99M$2.54M – $19.2M$9.25M (+32%)before first round–unknownD0%
1 Oct 2018$7.17M$2.61M – $19.7M$9.34M (+30%)before first round–unknownD0%
1 Nov 2018$7.36M$2.68M – $20.2M$9.42M (+28%)before first round–unknownD0%
1 Dec 2018$7.56M$2.75M – $20.8M$9.51M (+26%)before first round–unknownD0%
1 Jan 2019$7.76M$2.83M – $21.3M$9.59M (+24%)before first round–unknownD0%
1 Feb 2019$7.97M$2.90M – $21.9M$9.68M (+21%)before first round–unknownD0%
1 Mar 2019$8.17M$2.97M – $22.4M$9.76M (+19%)before first round–unknownD0%
1 Apr 2019$8.39M$3.05M – $23.1M$9.85M (+17%)before first round–unknownD0%
1 May 2019$8.61M$3.14M – $23.7M$9.94M (+15%)before first round–unknownD0%
1 Jun 2019$8.85M$3.22M – $24.3M$10.0M (+13%)before first round–unknownD0%
1 Jul 2019$9.08M$3.30M – $24.9M$10.1M (+11%)before first round–unknownD0%
1 Aug 2019$9.17M$3.34M – $25.2M$10.2M (+11%)before first round–unknownD0%
1 Sep 2019$9.25M$3.37M – $25.4M$10.3M (+11%)before first round–unknownD0%
1 Oct 2019$9.34M$3.40M – $25.6M$10.4M (+11%)before first round–unknownD0%
1 Nov 2019$9.42M$3.43M – $25.9M$10.5M (+11%)before first round–unknownD0%
1 Dec 2019$9.51M$3.46M – $26.1M$10.6M (+11%)before first round–unknownD0%
1 Jan 2020$9.59M$3.49M – $26.4M$10.7M (+11%)before first round–unknownD0%
1 Feb 2020$9.68M$3.52M – $26.6M$10.8M (+11%)before first round–unknownD0%
1 Mar 2020$9.76M$3.55M – $26.8M$10.9M (+11%)before first round–unknownD0%
1 Apr 2020$9.85M$3.59M – $27.1M$11.0M (+11%)before first round–unknownD0%
1 May 2020$9.94M$3.62M – $27.3M$11.1M (+11%)before first round–unknownD0%
1 Jun 2020$10.0M$3.65M – $27.6M$11.2M (+11%)before first round–unknownD0%
1 Jul 2020$10.1M$3.69M – $27.8M$11.3M (+11%)before first round–unknownD0%
1 Aug 2020$10.2M$3.72M – $28.1M$11.4M (+11%)before first round–unknownD0%
1 Sep 2020$10.3M$3.75M – $28.3M$11.5M (+11%)before first round–unknownD0%
1 Oct 2020$10.4M$3.79M – $28.6M$11.6M (+11%)before first round–unknownD0%
1 Nov 2020$10.5M$3.82M – $28.8M$11.7M (+11%)before first round–unknownD0%
1 Dec 2020$10.6M$3.86M – $29.1M$11.8M (+11%)before first round–unknownD0%
1 Jan 2021$8.86M$3.23M – $24.3M$9.87M (+11%)before first round5unknownD0%
1 Feb 2021$8.94M$3.25M – $24.6M$9.94M (+11%)before first round5unknownD0%
1 Mar 2021$9.02M$3.28M – $24.8M$10.0M (+11%)before first round5unknownD0%
1 Apr 2021$9.10M$3.31M – $25.0M$10.1M (+11%)before first round5unknownD0%
1 May 2021$9.18M$3.34M – $25.2M$10.2M (+11%)before first round5unknownD0%
1 Jun 2021$9.26M$3.37M – $25.4M$10.2M (+10%)before first round5unknownD0%
1 Jul 2021$9.35M$3.40M – $25.7M$10.3M (+10%)before first round5unknownD0%
1 Aug 2021$9.43M$3.43M – $25.9M$9.97M (+6%)before first round5unknownD0%
1 Sep 2021$9.52M$3.46M – $26.1M$9.64M (+1%)before first round5unknownD0%
1 Oct 2021$9.60M$3.50M – $26.4M$9.33M (-3%)before first round5unknownD0%
1 Nov 2021$9.69M$3.53M – $26.6M$9.01M (-7%)before first round5unknownD0%
1 Dec 2021$9.78M$3.56M – $26.9M$8.72M (-11%)before first round5unknownD0%
1 Jan 2022$9.87M$3.59M – $27.1M$8.42M (-15%)before first round5unknownD0%
1 Feb 2022$9.94M$3.62M – $27.3M$8.13M (-18%)before first round5unknownD0%
1 Mar 2022$17.0M$7.28M – $33.8M$15.3M (-10%)before first round18growingC0%
1 Apr 2022$17.1M$7.34M – $34.0M$15.0M (-13%)before first round18growingC0%
1 May 2022$17.3M$7.39M – $34.3M$14.7M (-15%)before first round18growingC0%
1 Jun 2022$17.4M$7.45M – $34.5M$14.4M (-17%)before first round18growingC0%
1 Jul 2022$17.5M$7.50M – $34.8M$14.1M (-19%)before first round18growingC0%
1 Aug 2022$12.5M$4.48M – $34.6M$10.0M (-20%)before first round18unknownD0%
1 Sep 2022$12.2M$4.35M – $34.5M$9.83M (-20%)before first round18unknownD0%
1 Oct 2022$12.0M$4.23M – $34.3M$9.64M (-20%)before first round18unknownD0%
1 Nov 2022$11.8M$4.11M – $34.1M$9.45M (-20%)before first round18unknownD0%
1 Dec 2022$11.6M$3.99M – $33.9M$9.26M (-20%)before first round18unknownD0%
1 Jan 2023$11.4M$3.87M – $33.7M$9.07M (-21%)before first round18unknownD0%
1 Feb 2023$11.2M$3.75M – $33.5M$8.88M (-21%)before first round18unknownD0%
1 Mar 2023$11.0M$3.65M – $33.3M$8.71M (-21%)before first round18unknownD0%
1 Apr 2023$10.8M$3.54M – $33.1M$8.52M (-21%)before first round18unknownD0%
1 May 2023$17.0M$6.47M – $38.1M$14.5M (-15%)before first round30growingC0%
1 Jun 2023$16.8M$6.31M – $38.1M$14.3M (-15%)before first round30growingC0%
1 Jul 2023$16.6M$6.16M – $38.1M$14.0M (-15%)before first round30growingC0%
1 Aug 2023$16.4M$6.01M – $38.0M$13.9M (-15%)before first round30growingC0%
1 Sep 2023$11.7M$3.60M – $38.0M$9.97M (-15%)before first round30unknownD0%
1 Oct 2023$11.5M$3.51M – $38.0M$9.88M (-14%)before first round30unknownD0%
1 Nov 2023$11.4M$3.42M – $37.9M$9.79M (-14%)before first round30unknownD0%
1 Dec 2023$11.2M$3.34M – $37.8M$9.71M (-14%)before first round30unknownD0%
1 Jan 2024$11.1M$3.25M – $37.8M$9.62M (-13%)before first round30unknownD0%
1 Feb 2024$10.9M$3.16M – $37.7M$9.53M (-13%)before first round30unknownD0%
1 Mar 2024$10.8M$3.09M – $37.6M$9.45M (-12%)before first round30unknownD0%
15 Mar 2024$911M$598M – $2.1B$1.4B (+50%)after a round41growingC0%
1 Apr 2024$928M$598M – $2.1B$1.4B (+47%)after a round41growingC0%
1 May 2024$959M$598M – $2.1B$1.4B (+42%)after a round41growingC0%
1 Jun 2024$993M$598M – $2.1B$1.4B (+37%)after a round41growingC0%
1 Jul 2024$1.0B$598M – $2.1B$1.4B (+33%)after a round41growingC0%
1 Aug 2024$1.1B$598M – $2.1B$1.4B (+28%)after a round41growingC0%
1 Sep 2024$1.1B$616M – $2.1B$1.4B (+26%)after a round47growingC0%
1 Oct 2024$1.2B$616M – $2.1B$1.4B (+22%)after a round47growingC0%
1 Nov 2024$1.2B$616M – $2.1B$1.4B (+17%)after a round47upC0%
1 Dec 2024$1.3B$640M – $2.2B$1.5B (+14%)after a round56growingC0%
1 Jan 2025$1.3B$640M – $2.2B$1.5B (+10%)after a round56growingC0%
1 Feb 2025$1.4B$640M – $2.2B$1.5B (+5%)after a round56growingC0%
1 Mar 2025$1.4B$640M – $2.2B$1.5B (+2%)after a round56growingC0%
1 Apr 2025$1.5B$645M – $2.2B$1.5B (0%)after a round56growingC0%
1 May 2025$1.5B$652M – $2.2B$1.5B (0%)after a round56growingC0%
1 Jun 2025$1.5B$660M – $2.2B$1.5B (0%)after a round56growingC0%
1 Jul 2025$1.5B$668M – $2.2B$1.5B (0%)after a round56growingC0%
1 Aug 2025$1.5B$708M – $2.3B$1.5B (0%)after a round69growingB0%
1 Sep 2025$1.5B$716M – $2.3B$1.5B (0%)after a round69growingB0%
1 Oct 2025$1.5B$725M – $2.3B$1.5B (0%)after a round69growingB0%
16 Oct 2025$2.1B$1.8B – $3.1B$2.7B (+30%)after a round69growingA0%
1 Nov 2025$2.1B$1.8B – $3.1B$2.7B (+28%)after a round69growingA0%
1 Dec 2025$2.2B$1.8B – $3.1B$2.7B (+26%)after a round78growingA0%
1 Jan 2026$2.2B$1.8B – $3.1B$2.7B (+23%)after a round78growingA0%
1 Feb 2026$2.3B$1.8B – $3.1B$2.7B (+20%)after a round78growingA0%
1 Mar 2026$2.3B$1.8B – $3.1B$2.7B (+18%)after a round78growingA0%
1 Apr 2026$2.4B$1.8B – $3.1B$2.7B (+15%)after a round78growingA0%
1 May 2026$2.4B$1.8B – $3.1B$2.7B (+13%)after a round78growingA0%
1 Jun 2026$2.6B$1.8B – $3.4B$3.0B (+14%)after a round117growingB0%
1 Jul 2026$2.7B$1.8B – $3.4B$3.0B (+11%)after a round117growingB0%
1 Aug 2026$2.8B$1.8B – $3.5B$3.0B (+8%)after a round122growingB0%
1 Sep 2026$2.9B$1.8B – $3.5B$3.0B (+4%)after a round122growingB0%
1 Oct 2026$2.7B$1.8B – $3.1B$2.7B (+1%)after a round77upA0%
24 Oct 2026$2.7B$1.8B – $3.1B$2.7B (0%)after a round77upA0%

Key facts about Tubulis

Founded
2016
Headquarters
Planegg, Germany
Employees
about 77 +12% in a year
Total raised
$496M
Funding rounds
2
Last round
Series C Oct 2025

Tubulis was founded in 2016 by Dominik Schumacher and Jonas Helma-Smets.

Tubulis funding history

Tubulis has 2 funding rounds on record, from Mar 2024 to Oct 2025, $496M in total. The latest disclosed valuation is $2.10B post-money (Series C, Oct 2025).

  1. Series C 15 Oct 2025

    Led by Venrock; with Wellington Management, Ascenta Capital, Nextech Invest, EQT, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds, OCCIDENT, Seventure Partners.

    Sources: tubulis.com, biopharmadive.com, anderapartners.com and 5 more

    $358M

    $2.10B post-money

  2. Series B 14 Mar 2024

    Led by EQT, Nextech Invest; with Frazier Life Sciences, Deep Track Capital, Andera Partners, BioMedPartners, Fund+, Bayern Kapital, Evotec, coparion, Seventure Partners, OCCIDENT, High-Tech Gründerfonds, EQT Life Science.

    Sources: tubulis.com

    $139M

Tubulis investors

18 investors have backed Tubulis; EQT, Nextech Invest and Venrock led at least one round.

  • EQT lead, 2 rounds
  • Venrock lead
  • EQT Life Science
  • Evotec
  • Frazier Life Sciences
  • Wellington Management

What Tubulis does

Tubulis works in pharmaceutical products, with 13 recorded offerings and customers in biotechnology, pharmaceuticals and healthcare.

Tubulis GmbH is a German biotechnology company engaged in the development of antibody-drug conjugates (ADCs) and protein-drug conjugates. The company utilizes proprietary technologies, including the Alco5 Conjugation Platform, to expand the therapeutic potential of ADCs for solid and hematologic tumors. Tubulis also provides discovery and development services for partners with antibody and chemical assets, and operates globally with offices in Munich, Cambridge, and Lausanne.

Description from Veridion's company data.

Products and services

  • Antibody-Drug Conjugate Development
  • Protein-Drug Conjugate Engineering
  • Biophysical Property Optimization of ADCs
  • Proprietary Conjugation Platform Utilization
  • Antibody and Chemical Asset Advancement
  • Disease-Specific Biology Application
  • ADC Pipeline Expansion
  • Solid Tumor Therapeutic Development
  • Hematologic Tumor Therapeutic Development
  • ADC Technology Licensing
  • ADC Technology Transfer Services
  • Oncology Therapeutic Consulting
  • ADC Industry Event Participation

Markets

  • Biotechnology
  • Pharmaceuticals
  • Healthcare

Technology

  • Proprietary Conjugation Platform for Antibody-Drug Conjugates

Business model

  • Business-to-Business
  • Manufacturing

Industry codes (NAICS)

  • 325414 Biological Product (except Diagnostic) Manufacturing 100% match

Questions about Tubulis

What is Tubulis worth?

Valuation $2.7B (range $1.8B to $3.1B), as of 24 Oct 2026. The last disclosed valuation was $2.10B (Series C, Oct 2025).

Has Tubulis raised money?

Tubulis has 2 funding rounds on record, from Mar 2024 to Oct 2025, $496M in total. The latest disclosed valuation is $2.10B post-money (Series C, Oct 2025).

Who has invested in Tubulis?

EQT, Nextech Invest, Venrock, Andera Partners, Bayern Kapital and Deep Track Capital, and 12 more. Lead investors include EQT, Nextech Invest and Venrock.

How many people work at Tubulis?

About 77, up 12% over the last year. Headcount rose from 5 in Jan 2021 to 122 in Jul 2026, then fell to 77 in Sep 2026.

What does Tubulis do?

Tubulis works in pharmaceutical products, with 13 recorded offerings and customers in biotechnology, pharmaceuticals and healthcare. Its main offerings are antibody-drug conjugate development, protein-drug conjugate engineering and biophysical property optimization of ADCs.

When was Tubulis founded, and where is it based?

Tubulis was founded in 2016 and is based in Planegg, Germany. It has about 77 employees, up 12% over the last year.

How we value companiesReport an issue